Treace Medical Concepts/$TMCI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Treace Medical Concepts
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Ticker
$TMCI
Sector
Primary listing
Industry
Health Care Equipment and Supplies
Headquarters
Employees
477
Website
TMCI Metrics
BasicAdvanced
$352M
-
-$0.85
0.80
-
Price and volume
Market cap
$352M
Beta
0.8
52-week high
$10.79
52-week low
$4.54
Average daily volume
284K
Financial strength
Current ratio
4.504
Quick ratio
3.231
Long term debt to equity
63.876
Total debt to equity
65.847
Interest coverage (TTM)
-9.95%
Profitability
EBITDA (TTM)
-44.278
Gross margin (TTM)
80.25%
Net profit margin (TTM)
-25.13%
Operating margin (TTM)
-24.78%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-14.56%
Return on equity (TTM)
-45.73%
Valuation
Price to revenue (TTM)
1.656
Price to book
3.34
Price to tangible book (TTM)
4.16
Price to free cash flow (TTM)
-9.445
Free cash flow yield (TTM)
-10.59%
Free cash flow per share (TTM)
-0.593
Growth
Revenue change (TTM)
7.54%
Earnings per share change (TTM)
-4.03%
3-year revenue growth (CAGR)
26.25%
3-year earnings per share growth (CAGR)
18.19%
What the Analysts think about TMCI
Analyst ratings (Buy, Hold, Sell) for Treace Medical Concepts stock.
Bulls say / Bears say
Treace Medical Concepts reported Q1 2025 revenue of $52.6 million, a 3% year-over-year increase, and improved its net loss by 15% to $(15.9) million, indicating positive financial momentum. (stocktitan.net)
The company has expanded its product portfolio with limited releases of Nanoplasty™, Percuplasty™ 3D MIS Osteotomy Systems, and SpeedMTP™ MTP Fusion System, potentially driving future revenue growth. (stocktitan.net)
Analysts have set an average 12-month price target of $10.21 for TMCI, suggesting a potential upside from its current trading price. (americanbankingnews.com)
Treace Medical Concepts filed a patent infringement lawsuit against Zimmer Biomet Holdings and Paragon 28, which could lead to prolonged legal battles and associated costs. (stocktitan.net)
The company reported a net loss of $(15.9) million in Q1 2025, indicating ongoing profitability challenges. (stocktitan.net)
Increased competition from minimally invasive surgery (MIS) osteotomy solutions and knockoffs of Treace's Lapiplasty® products have led to a downward revision of the company's 2024 revenue guidance. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TMCI Financial Performance
Revenues and expenses
TMCI Earnings Performance
Company profitability
TMCI News
AllArticlesVideos
Securities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025
Accesswire·2 months ago
Securities Class Action Lawsuit Filed Against Treace Medical Concepts, Inc. (TMCI) - Levi & Korsinsky Represents Shareholders
Accesswire·2 months ago
Lost Money on Treace Medical Concepts, Inc. (TMCI)? Join Class Action Before June 10, 2025 - Contact Levi & Korsinsky
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Treace Medical Concepts stock?
Treace Medical Concepts (TMCI) has a market cap of $352M as of July 30, 2025.
What is the P/E ratio for Treace Medical Concepts stock?
The price to earnings (P/E) ratio for Treace Medical Concepts (TMCI) stock is 0 as of July 30, 2025.
Does Treace Medical Concepts stock pay dividends?
No, Treace Medical Concepts (TMCI) stock does not pay dividends to its shareholders as of July 30, 2025.
When is the next Treace Medical Concepts dividend payment date?
Treace Medical Concepts (TMCI) stock does not pay dividends to its shareholders.
What is the beta indicator for Treace Medical Concepts?
Treace Medical Concepts (TMCI) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.